Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Correction

Published on 27 Jun 2023

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

in Cancer Molecular Targets and Therapeutics

Yulong Fu
Anqi Wang
Jieqi Zhou
Wei Feng
Minhua Shi
Xiao Xu
Hongqing Zhao
Liming Cai
Jian Feng
Xuedong Lv

Frontiers in Oncology

doi 10.3389/fonc.2023.1236311

1,357 views

Correction

Published on 27 Jun 2023

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

in Cancer Molecular Targets and Therapeutics

Wei-Wei Zuo
Chun-Fang Zhao
Yan Li
Hai-Yan Sun
Guo-Ming Ma
Yue-Ping Liu
Shan Kang

Frontiers in Oncology

doi 10.3389/fonc.2023.1218746

1,043 views

Original Research

Published on 23 Jun 2023

An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma

in Cancer Molecular Targets and Therapeutics

Dong Zhang
Xi Zhang
Zhanpeng Liu
Tian Han
Kai Zhao
Xinchi Xu
Xu Zhang
Xiaohan Ren
Chao Qin

Frontiers in Oncology

doi 10.3389/fonc.2023.1207068

4,957 views
16 citations

Review

Published on 23 Jun 2023

Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy

in Cancer Molecular Targets and Therapeutics

Yuting Jia
Bin Guo
Wenbin Zhang
Feng Wang
Yong Zhang
Quanmao Zhang
Erfeng Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1110207

7,345 views
10 citations

Mini Review

Published on 20 Jun 2023

Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy

in Cancer Molecular Targets and Therapeutics

Teng Tu
Hongying Zhang
Huanji Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1197502

3,904 views
4 citations

Original Research

Published on 19 Jun 2023

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

in Cancer Molecular Targets and Therapeutics

Jiuhui Xu
Chenglong Chen
Kunkun Sun
Qianyu Shi
Boyang Wang
Yi Huang
Tingting Ren
Xiaodong Tang

Frontiers in Oncology

doi 10.3389/fonc.2023.1192472

2,428 views
4 citations

Original Research

Published on 19 Jun 2023

Lestaurtinib inhibits Citron kinase activity and medulloblastoma growth through induction of DNA damage, apoptosis and cytokinesis failure

in Cancer Molecular Targets and Therapeutics

Gianmarco Pallavicini
Giorgia Iegiani
Roberta Parolisi
Alessia Ferraro
Francesca Garello
Valeria Bitonto
Enzo Terreno
Marta Gai
Ferdinando Di Cunto

Frontiers in Oncology

doi 10.3389/fonc.2023.1202585

2,585 views
1 citation

Review

Published on 19 Jun 2023

The role of Vps4 in cancer development

in Cancer Molecular Targets and Therapeutics

Li Juan Huang
Shi Tong Zhan
Yu Qin Pan
Wei Bao
Ye Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1203359

7,473 views
5 citations

Clinical Trial

Published on 14 Jun 2023

A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis

in Cancer Molecular Targets and Therapeutics

Gabriel Oliveira Bernardes Gil
Warne Pedro de Andrade
Paulo Henrique Costa Diniz
Farley Soares Cantidio
Izabella Nobre Queiroz
Maria Luísa Braga Vieira Gil
Conceição Aparecida Medeiros Almeida
Paola Palmer Reis Caldeira
Marcos Regalin
Agnaldo Lopes Silva-Filho

Frontiers in Oncology

doi 10.3389/fonc.2023.1202544

3,387 views
5 citations

Review

Published on 14 Jun 2023

The use of plant-derived exosome-like nanoparticles as a delivery system of CRISPR/Cas9-based therapeutics for editing long non-coding RNAs in cancer colon cells

in Cancer Molecular Targets and Therapeutics

Tatiana Hillman

Frontiers in Oncology

doi 10.3389/fonc.2023.1194350

6,013 views
13 citations

Original Research

Published on 13 Jun 2023

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

in Cancer Molecular Targets and Therapeutics

Katharine Yu
Amrita Basu
Christina Yau
Denise M. Wolf
Hani Goodarzi
Sourav Bandyopadhyay
James E. Korkola
Gillian L. Hirst
Smita Asare
Angela DeMichele

Frontiers in Oncology

doi 10.3389/fonc.2023.1192208

2,843 views
1 citation

Original Research

Published on 12 Jun 2023

Early in vitro evidence indicates that deacetylated sialic acids modulate multi-drug resistance in colon and lung cancers via breast cancer resistance protein

in Cancer Molecular Targets and Therapeutics

Isaac Tuffour
Setor Amuzu
Hala Bayoumi
Iram Surtaj
Colin Parrish
Rachel Willand-Charnley

Frontiers in Oncology

doi 10.3389/fonc.2023.1145333

4,376 views
6 citations

Review

Published on 12 Jun 2023

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma

in Cancer Molecular Targets and Therapeutics

Binhao Shi
Junli Chang
Xingyuan Sun
Xiaoping Ma
Peng Zhao
Chujie Zhou
Yongjun Wang
Yanping Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1148735

2,393 views
4 citations

Original Research

Published on 08 Jun 2023

Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment

in Cancer Molecular Targets and Therapeutics

Song Liao
Jianxiong Li
Song Gao
Yuchen Han
Xinli Han
Yanan Wu
Jingyou Bi
Meng Xu
Wenzhi Bi

Frontiers in Oncology

doi 10.3389/fonc.2023.1158857

4,077 views
9 citations

Original Research

Published on 05 Jun 2023

Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients

in Cancer Molecular Targets and Therapeutics

Deliang Gong
Qingzhong Zhao
Jun Liu
Shibing Zhao
Chengfeng Yi
Jianwei Lv
Hang Yu
Erbao Bian
Dasheng Tian

Frontiers in Oncology

doi 10.3389/fonc.2023.1169430

2,105 views
1 citation

Original Research

Published on 05 Jun 2023

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

in Cancer Molecular Targets and Therapeutics

Howard Fine
Tony Reid
Scott Caroen
Bryan Oronsky
Nacer Abrouk
Nicholas Butowski

Frontiers in Oncology

doi 10.3389/fonc.2023.1176448

3,094 views
7 citations